Eli Lilly's third-quarter sales jumped 39% to $24.397 billion as surging demand outweighed lower realized prices, offering evidence that its GLP-1 manufacturing scale is improving the economics of growth. But the October 29 results were less straightforward than that headline suggests. Roughly $900 million of revenue benefits flattered sales, while $4.2 billion of acquired research charges complicated earnings. At the prior day's closing price, the shares cost about 36.3 times the newly issued full-year earnings guidance, making the distinction between demonstrated operating strength and future drug-development returns especially important.
More volume, lower prices, better margins
Lilly's third-quarter release reported worldwide volume growth of 53% alongside 15% lower realized prices. The most persuasive evidence of scale was the combination of that pricing pressure with expanding gross margins: the reported margin rose 100 basis points to 83.9%, while the non-GAAP margin increased 80 basis points to 84.4%. Lilly attributed the improvement to product mix and production efficiencies, partly offset by lower prices.
The geographic split shows why pricing cannot be dismissed. U.S. revenue increased 34% to $15.1 billion, with volume up 41% and realized prices down 7%. Outside the U.S., revenue rose 47% to $9.3 billion as volume climbed 76%, but realized prices fell 29%. China's National Reimbursement Drug List pressured Mounjaro pricing. Our interpretation is that Lilly is demonstrating an ability to profit from broader access, although this quarter does not establish how far future price concessions can go without weakening returns.
Mounjaro remained the principal growth engine, with sales rising 65% to $10.723 billion. Its U.S. sales increased 41% to $5.0 billion, while international sales rose 93% to $5.7 billion. Zepbound revenue grew 49% to $5.352 billion. Together, the two products generated approximately two-thirds of company revenue, a calculation that highlights both the strength of Lilly's position and its substantial reliance on this franchise.
Strong operations do not erase earnings complications
Revenue quality requires a separate adjustment. The approximately $900 million of benefits included $410 million in Jardiance sales milestones and favorable changes to rebate and discount estimates. No further Jardiance milestones remain. These items do not invalidate the volume story, but investors should not treat all reported revenue growth as a repeatable increase in prescriptions or demand.
The expense picture also separates ongoing investment from acquisition spending. Research and development expense rose 23% to $4.2 billion, equivalent to 17% of revenue, while marketing, selling and administrative expenses increased 14% to $3.1 billion. Both grew more slowly than sales, supporting operating leverage in the reported quarter, although the revenue benefits make that comparison somewhat more favorable.
Separately, acquired in-process research and development charges reached $4.2 billion, versus $656 million a year earlier, mainly from AtaiBeckley and Curevo. Their EPS impact increased to $4.57 from $0.71. Such charges differ from the recurring cost of manufacturing existing medicines, but they are not economically irrelevant: purchasing pipeline assets commits capital whose eventual payoff remains uncertain.
Reported net income increased 16% to $6.451 billion, and reported EPS rose 16% to $7.22. Non-GAAP net income grew 6% to $6.679 billion, while non-GAAP EPS increased 7% to $7.48. The gap between rapid revenue growth and slower earnings growth cautions against judging the quarter solely by sales. Equally, the acquisition charges mean these earnings figures do not provide a clean measure of the underlying operating improvement.
The valuation depends on tomorrow's pipeline returns
Lilly raised full-year revenue guidance to $91 billion–$92 billion from $85 billion–$87 billion and lifted performance-margin guidance to 52.0%–52.5% from 49.0%–50.5%. Yet non-GAAP EPS guidance fell to $35–$36 from $35.50–$36.50. The apparent contradiction is explained by a $4.07 improvement in the underlying EPS outlook at the midpoint, outweighed by the quarter's $4.57 acquired-research charge. Guidance excludes acquired in-process research and development after September 30.
At the October 28 closing price of $1,288.30, Lilly traded at 36.29 times the revised $35.50 EPS midpoint. This is a calculated guidance-based multiple, not a trailing P/E. Because the guidance includes acquired-research charges, the multiple is not a pure measure of recurring operating earnings. Nevertheless, our assessment is that the price demands continued commercial execution and productive reinvestment, not simply another quarter of higher volumes.
There is tangible pipeline and regulatory support. The FDA approved Mounjaro for cardiovascular risk reduction. Separately, Lilly's October 28 retatrutide topline results reported 80-week A1C reductions of 2.2 percentage points versus 1.8 with Ozempic 2 mg, and weight loss of 19.5%–20.9% versus 9.4%. Retatrutide remains investigational and unapproved; detailed results have not yet been peer-reviewed.
The quarter therefore supports a qualified answer: Lilly's scale absorbed lower pricing while improving gross margins, but that achievement does not establish the durability of every revenue dollar or the value of acquired pipeline assets. The premium becomes defensible only if expanding access sustains profitable growth and research spending produces valuable medicines. Today's manufacturing advantage is demonstrated; tomorrow's investment returns are still to be earned.
